Investigating the gut microbiota as a mediator of metformin’s effects on systemic and tumor immunity in diabetic OSCC patients could clarify whether a similar mechanism exists or if metformin’s impact on PD-L1 expression in OSCC is more complex. This evidence concerns the gene CD274 and neoplasm.